

Express Mail No. EV 687 633 019 US

INFORMATION DISCLOSURE STATEMENT

Address to: Mail Stop RCE Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

	17-		
Attorney Docket	RICE-012		
First Named Inventor	DALY, ROGER JOHN		
Application Number	09/509,196		
Confirmation No.	8868		
Filing Date	March 23, 2000		
Group Art Unit	1646		
Examiner Name	CHERNYSHEV, OLGA N.		
Title: "A POTENTIA	I FFFECTOR FOR THE GRR7		

Title: "A POTENTIAL EFFECTOR FOR THE GRB7 FAMILY OF SIGNALLING PROTEINS"

Sir:

This is an Information Disclosure Statement submitted for the Examiner's consideration. A Form PTO-SB/08A listing the references and copies of the cited references accompany this paper. Applicants would appreciate the Examiner's initialing and returning the form to indicate that the references have been reviewed and made of record.

This Information Disclosure Statement is not intended as a representation that a search has been made, that additional information material to the examination of this application does not exist, or that any one of the above references constitutes prior art to the present application within the meaning of 35 U.S.C.§102.

As applicants have not yet received a first Action on the merits, no fee is believed to be required for filing this Disclosure Statement. If, however, the PTO finds that for some reason a fee is due, our Deposit Account No. 50-0815, Order No. RICE-012 may be charged thereon.

Date:

BOZICEVIC, FIELD & FRANCIS LLP 1900 University Avenue, Suite 200

East Palo Alto, California 94303

Telephone: (650) 327-3400 Facsimile: (650) 327-3231

By:

Carol L. Francis/ Registration No. 36,513

Respectfully submitted,

BOZICEVIC, FIELD & FRANCIS LLP

PTO/SB/08a (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

RICE-012

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE U.S. DEPARTMENT OF COMMERCE Inder the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Complete if Known

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(use as many sheets as necessary)

Complete if Known

Application Number

99/509,196

Filing Date

March 23, 2000

First Named Inventor

Art Unit

1646

Examiner Name

CHERNYSHEV, OLGA N.

Attorney Docket Number

	U.S. PATENT DOCUMENTS					
Examiner Cite Document Number		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant		
minais	140.	Number-Kind Code ² (if known)	IVIIVI-DD-1111	Applicant of Cited Document	Figures Appear	
		US-				
		US-				

of

Sheet

FOREIGN PATENT DOCUMENTS						
Examiner Initials'	Cite No. ¹	Foreign Patent Document Country Code ³ –Number ⁴ –Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶

	NON PATENT LITERATURE DOCUMENTS				
		Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	Τ²		
		Daly "The Grb7 Family of Signalling Proteins" Cell Signal (1998) 10:613-618.			
		Daly et al. "Cloning and Characterization of <i>GRB14</i> , a Novel Member of the GRB7 Gene Family" <i>J. Biol. Chem.</i> (1996) 271:12502-12510			
		Kishi et al. "Molecular cloning of human GRB-7 co-amplified with CAB1 and c-ERBB-2 in primary gastric cancer." Biochem Biophys Res Commun. (March 1997) 232(1):5-9			
		Lyons et al. "Identification of a novel human tankyrase through its interaction with the adaptor protein Grb14" J Biol Chem. (May 2001) 276(20):17172-80 (Epub 2001 Feb 22)			
		Tanaka et al. "Coexpression of Grb7 with epidermal growth factor receptor or Her2/erbB2 in human advanced esophageal carcinoma." Cancer Res. (Jan 1997) 57(1):28-31			
		Stein et al. "The SH2 domain protein GRB-7 is co-amplified, overexpressed and in a tight complex with HER2 in breast cancer." EMBO J. (Mar. 1994) 13(6):1331-40			

Examiner	Date	
Signature	Considered	
_		

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SB/08a (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Page thute for form 1449A/PTO Complete if Known Application Number 09/509,196 INFORMATION DISCLOSURE Filing Date March 23, 2000 STATEMENT BY APPLICANT First Named Inventor DALY, ROGER JOHN Art Unit

(use as many sheets as necessary)

Examiner Name CHERNYSHEV, OLGA N. Sheet Attorney Docket Number RICE-012

_	NON PATENT LITERATURE DOCUMENTS			
Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²		
т —				
	Margolis et al, "High-efficiency expression/cloning of epidermal growth factor-receptor-binding proteins with Src homology 2 domains", Proc. Natl. Acad. Sci, 1992, vol. 89, pp. 8894-8898.			
	Janes et al., "Structural determinants of the interaction between the erbB2 receptor and the Src homology 2 domain of Grb7", The journal of Biological Chemistry, 1997, vol. 272, no. 13, 8490-8497			
	·			
	·			
	Cite No. ¹	No.1 Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. Margolis et al, "High-efficiency expression/cloning of epidermal growth factor-receptor-binding proteins with Src homology 2 domains", Proc. Natl. Acad. Sci, 1992, vol. 89, pp. 8894-8898. Janes et al., "Structural determinants of the interaction between the erbB2 receptor and the Src homology 2 domain of Grb7", The journal of Biological Chemistry, 1997, vol. 272, no. 13,		

Examiner	Date	,
Signature	Considered	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.